Cleantech Building Materials: Unaudited Preliminary Results to 31 December 2019


26 March 2020



Cleantech Building Materials plc

Unaudited Preliminary Results to 31 December 2019

Cleantech Building Materials plc (“CBM” or the “Company” or the “Group”), presents its results for the twelve months ended 31 December 2019.  The unaudited financial statements are appended to this announcement.

These results are unaudited because as a consequence of the Covid-19 pandemic our auditors, Crowe U.K. LLP, are presently unable to sign the Audit Report on these financial statements, whilst they consider the impact of these circumstances on going concern and subsequent events. These accounts have been prepared in accordance with the rules and standards applicable at this time. It is possible that these rules may be changed in light of the Covid-19 situation, before our auditors sign their Audit Report, which may require a change in these accounts. We will announce our audited results, as soon as they are available and highlight any differences from these results.

The Directors are not proposing the payment of a dividend.

Chairman’s Statement

2019 has been a breakthrough year for CBM and its strategy to build an Accoya® wood factory in China.

On 9 July 2019, CBM’s subsidiary company Diamond Wood China Limited (“DW”) signed a legally binding Investment Framework Agreement with Nantong Acetic Acid Company (“NTAAC”) to provide circa US $50m in equity and debt financing for the first Accoya® wood factory in China. DW will be the majority shareholder in the joint venture, and will additionally receive a substantial royalty on profits. NTAAC is amongst China’s top speciality chemical companies, serving global clients in the US and Europe. The company is listed on the Shanghai Stock exchange.

On 10 July 2019, we announced the signing of a subscription agreement with a family office for €15m euros (“Investor”). These funds will be used to finance the Group’s share of the equity financing for the joint venture with NTAAC.

In November 2019, the Bank of Jiangsu provided DW and NTAAC with a signed MOU committing to provide €22m euros of debt financing. In China, such a signed commitment document is unusual, and attests to the strength of the Accoya® wood factory project, and the long relationship between NTAAC and Bank of Jiangsu.

On 12 December 2019, the Administration Committee of Jiangsu Rudong Yangkou Port Economic Development Zone provided DW and NTAAC with a signed commitment letter identifying the plot of land reserved for the Diamond Wood Accoya® wood factory.

During the course of 2019 we continued to invest in the development of our marketing and sales operations in China and the ASEAN countries, which resulted in new offtake agreements being added to the growing list of manufacturers and wholesalers in the region committing to purchase significant volumes of Accoya® wood from the Group. These agreements, and the ongoing business with our existing base of distribution partners, attest to a strong and increasing demand for Accoya® wood in the region.

It is the Board’s view that there is sufficient demand in China and the ASEAN territories to warrant the construction of our own Accoya® wood factory. DW previously purchased the exclusive licence to sell and produce Accoya® wood in those regions from Accsys’ subsidiary Titan Wood Limited (“TW”) for circa €20m euros.

The recent 2019 agreement with NTAAC, and the subscription agreement signed by CBM with the Investor, are the foundations for the build out of DW’s strategy to manufacture and sell its own Accoya® wood. DW’s wholesalers and manufacturers are demanding such a stable and cost-competitive source of Accoya® wood.

At this time, the Covid-19 outbreak has not impacted our timetable, as we have been able to progress discussions and planning for the joint venture. However, if there is a prolonged travel ban, then there will inevitably be some delays, and we will work to keep any such delays to a minimum. The Worldwide spread of Covid-19 is clearly very concerning and will have an impact on the World Economy. Our business is focussed on China and at the time of writing the rate of infection in China is falling. Our team and our partners NTACC have worked well remotely and we have not experienced any delays. At this time we do not currently expect restrictions to combat the Covid-19 virus in China to impact our timetable for moving forward with NTACC. We are an English company, with a majority of the Board based in the UK. As our CEO and CFO are based in Shanghai, our meetings are held remotely and accordingly the impact of the disruption to normal business caused by measures to combat the Covid-19 virus is anticipated to have limited impact on how the Board of the Company manages its business.

Simon Allocca joined the Board this year.  Simon’s many years as a senior banker have added to the Board’s skill sets and he has made an immediate contribution.

The Group reported a loss of €4,490,000 for the 12 months ended 31 December 2019 (2018: €4,661,000), which reflects the fact that the Group has borne the cost of its infrastructure and staff.

I would like to take this opportunity to again express my sincere gratitude to my fellow Directors and staff for their hard work and commitment over the past year.

I look forward to providing you with further updates at our next Annual General Meeting (“AGM”). The timing of that AGM and the release of our audited Annual Report for 2019 is subject to uncertainty due to the impact of the Covid-19 virus. We will inform the market further once we are able to provide definitive dates.

Strategy and Objectives

The Group’s primary strategic objectives for 2020 are to:

  1. To engage a leading engineering, procurement and construction firm to lead the construction of an Accoya® wood manufacturing facility in China.
  2. Together with the Group’s chemical industry joint venture partner, NTAAC, to ensure that the Accoya® wood manufacturing facility is constructed on time and on budget, and operated efficiently.
  3. To grow sales of Accoya® wood to regional wholesalers.
  4. To build relationships with large-volume wood product manufacturers through testing and trials in anticipation of Accoya® wood being produced in the Group’s own factory.
  5. To develop the Group’s marketing and sales initiatives to further expand market channels and offtake agreements in the Chinese and ASEAN markets.

Financial Overview

The Group’s revenues for the 12 months ended 31 December 2019 remained steady at €927,000 (2018: €703,000) and consisted mainly of Accoya® wood sales to customers in Thailand, Vietnam, Singapore, Indonesia and Malaysia.

The Group realised a net loss of €4,490,000 for the year to 31 December 2019 (2018: €4,661,000). As at 31 December 2019, the Group had cash and cash equivalents of €283,000 (2018: €8,000) as well as an available facility of approximately €2.5m, and an equity commitment to finance the Joint Venture of an additional €15m euros. The Company has significantly reduced its outstanding debts during 2019, and now has net current liabilities of €588,000 (2018: €1,531,000).

We did not see any increase in the amount of Accoya® wood we received this year and as a consequence of this shortage, DW’s channel partners have been unable to tender large-volume construction projects, and our manufacturing customers have had to delay their market launch plans. This inability to serve the growing demand in the region has been a frustrating development for all concerned

Once the Group is producing its own AccoyaÒ wood, the Board believes the financial performance of the Group will be radically transformed.

Future Developments

The Group continues to advance its discussions with potential partners to significantly grow its business and to construct and operate its own AccoyaÒ wood manufacturing facility. The Group expects to commence construction of its own Accoya® wood manufacturing facility during 2020.

The Company’s next financial report will be unaudited accounts for the six months to 30 June 2020 which we plan to publish in August 2020. We will inform the market accordingly should the impact of the Covid-19 virus cause this date to change.


Further information may be found at the Company's website at

Further Enquiries:

Cleantech Building Materials plc
Adrian Wyn-Griffiths
+44 20 3934 6630

Keswick Global AG (Certified Adviser)
+43 1 740 408045

IFC Advisory Limited (Financial PR)
Tim Metcalfe
Zach Cohen
+44 20 3934 6630

The information communicated in this announcement is “inside information” for the purposes of article 7 of the Market Abuse Regulation 596/2014.


About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer2.6.2020 07:00:00 CESTPress release

Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or metastatic hepatocellular carcinoma Tecentriq combination improved overall survival and progression-free survival compared to the previous standard of careApplication approved under FDA’s Project Orbis initiative and Real-Time Oncology Review pilot programme Basel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy. “We’re excited that today’s approval of Tecentriq in combination with Avastin for unresectable or metastatic hepatocellular carcinoma brings a cancer immunotherapy option to people with this aggressive form of liver cancer,” said Levi Garraway, M.D., Ph.D., Chief Medi

EXEL INDUSTRIES :2019-2020 First-Half Results The initial benefits of our reorganization blacked out by the impact of the health crisis and depreciation of goodwill 1st semester 20191st semester 20202.6.2020 07:00:00 CESTPress release

PRESS RELEASE Paris, June 2, 2020 2019-2020 First-Half Results The initial benefits of our reorganization blacked out by the impact of the health crisis and depreciation of goodwill 1st semester 20191st semester 2020in M€Oct 18 - Mar 19Oct 19 - Mar 20Revenue348.9314.3Current Operating Income5.0-1.1%1.4%-0.3%Non-recurring items-4.2-28.9Financial expenses-1.9-1.8(Losses)/gains on foreign exchange2.9-4.4Profit before tax1.7-36.2Tax expense-0.7-0.4Share of profit of associates0.20.2Net income 1.2-36.4 ·Analysis of 2019-2020 first-half results The decline in current operating income over the first-half of 2019-2020 was due primarily to the drop in revenue from Agricultural and Industrial Spraying due to the global health crisis. The reorganization initiated in 2019 produced visible results for the Sugar Beet Harvesting business. With respect to Agricultural Spraying, we expect an improvement by the end of the financial year. The very uncertain macro-economic context, notably as a result of

Mitsubishi Corporation and NTT complete acquisition of 30% stake in HERE Technologies2.6.2020 07:00:00 CESTPress release

June 2, 2020 Amsterdam and Tokyo – HERE Technologies today announced that Mitsubishi Corporation (MC) and Nippon Telegraph and Telephone Corporation (NTT) of Japan have completed their joint acquisition of a 30% ownership stake in the company, after receiving regulatory approvals. HERE welcomes MC and NTT as strategic investors. The two companies have co-invested in HERE via their recently established, jointly owned holding company COCO Tech Holding B.V. in the Netherlands. As a result, HERE now has nine direct and indirect shareholders: Audi, Bosch, BMW Group, Continental, Intel Capital, MC, Mercedes-Benz, NTT and Pioneer.​ Following the transaction, HERE has added two new members to its Supervisory Board: Mr. Yutaka Kyoya, Executive Vice President, Group CEO, Consumer Industry Group, Mitsubishi Corporation; and Mr. Hiroki Kuriyama, Member of the Board, Executive Vice President, Head of Strategic Business Development, NTT. HERE’s broadened shareholder structure supports the company’s

Prosafe SE: Update on financial situation and process with lenders2.6.2020 07:00:00 CESTPress release

Prosafe refers to the information on its financial status and process with lenders that has been provided over time and lastly in the Q1 2020 report published on 26 May 2020. The company has gained support to an extension to the previously reported forbearance arrangement with a majority of its lenders across its USD 1,300 million and USD 288 million facilities from end May 2020 till end June 2020. As part of this, the company will continue to defer making payments of scheduled instalments and interests under both facilities. Similarly, payment of the final instalment owed and due under the seller credit to Cosco for the Safe Notos remains as initially reported on 13 February subject to ongoing discussions with Cosco and the lenders. The company's discussions with its lenders remain constructive. The forbearance arrangement shows support for the company and creates stability to work with lenders to agree a long term financial solution, while lenders reserve their rights. Pending this,

EVS Broadcast Equipment reports update of share buyback program2.6.2020 06:45:00 CESTPress release

Publication on June 2, 2020, before market opening Regulated information – reporting share buyback EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports update of share buyback program EVS Broadcast Equipment reports that the following transactions, conducted within the framework of the share buyback program announced on May 6, 2020, took place between May 25, 2020 and May 29, 2020. DateNumber of shares acquiredAverage price (EUR)Total (EUR)25/05/20202,500 13.7820 34,45526/05/20202,500 13.9834 34,95927/05/20202,500 14.2910 35,72828/05/20202,500 14.8076 37,01929/05/20202,500 14.4971 36,243Total12,50014.2722 178,403 As of May 29, 2020, and since the start of the buyback program, EVS has bought 27,267 shares at an average price of EUR 14,0123, representing in total EUR 382,072. After aforementioned transactions the total number of own shares amounts now to 618,319 shares as of May 29, 2020 (including 607,332 shares already held by the

Nexstim Abp: Preliminärt utfall av den lyckade företrädesemissionen1.6.2020 19:30:00 CESTPressemelding

Företagsmeddelande, insiderinformation, Helsingfors 1 juni 2020 kl. 20.30 (EEST) Nexstim Abp: Preliminärt utfall av den lyckade företrädesemissionen FÅR EJ PUBLICERAS ELLER SPRIDAS DIREKT ELLER INDIREKT I FÖRENTA STATERNA, AUSTRALIEN, SYDAFRIKA, HONGKONG, JAPAN, KANADA, SINGAPORE ELLER NÅGON ANNAN STAT DÄR SPRIDNINGEN ELLER PUBLICERINGEN STRIDER MOT LAGEN. Teckningstiden för Nexstim Abp:s (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) företrädesemission om cirka 2,3 miljoner euro (”emissionen”) avslutades 25 maj 2020 i Sverige och 27 maj 2020 i Finland. Enligt det preliminära emissionsutfallet övertecknades emissionen och cirka 273 procent av de tilldelade aktierna tecknades. Av de tilldelade 376 719 780 nya aktierna (”emissionsaktierna”) tecknades 336 033 654 emissionsaktier (cirka 89,2 procent av emissionsaktierna) med företrädesrätt och 40 686 126 emissionsaktier (cirka 10,8 procent av emissionsaktierna) tilldelas i enlighet med emissionsvillkoren. Enligt det preliminära emissio